The impact of being overweight on outcome after hematopoietic SCT (HSCT) is controversial. We performed meta-analyses to evaluate the impact of being overweight on acute graft-versus-host disease (aGVHD) risk and survival. Original data were obtained from MEDLINE, and studies that evaluated being overweight before transplantation in recipients as a risk factor for aGVHD or a prognostic factor for overall survival (OS) were extracted. Study-specific relative risks on the log scale comparing overweight with non-overweight patients were used to obtain a pooled RR with 95% confidence interval (CI). We identified 8 studies of aGVHD and 21 of OS. In allogeneic HSCT, the meta-analysis determined statistically significant associations of overweight recipients with aGVHD risk and OS. Meta-analysis of the 8 studies of aGVHD indicated that the RR for overweight to non-overweight patients was 1.186 (95% CI: 1.072-1.312). Regarding OS, meta-analysis of 11 allogeneic HSCT studies indicated that the RR for overweight to nonoverweight patients was 1.163 (1.009-1.340). Our results indicate that being overweight before transplantation in recipients is associated with a high aGVHD rate and worse survival after allogeneic HSCT. Potential heterogeneity especially in adult/pediatric patients limits the interpretability of our finding. Further, well-designed large cohort studies are warranted.
INTRODUCTION
Obesity is an increasingly prominent health problem, particularly in developed countries. 1 The WHO (World Health Organization) estimates that more than 1 billion adults are overweight around the world. 1, 2 Overweight and obese persons are at increased risk for a number of medical conditions, including type II diabetes, cardiovascular diseases and several cancers, which means that these persons are more likely to suffer further morbidity and mortality. 1, [3] [4] [5] Obesity is also a potential cause of variability in treatment outcomes. Particularly in chemotherapy, being overweight may affect outcomes through changes to dose settings and pharmacokinetics and the presence of comorbidities. 6, 7 The effect of being overweight or obese on outcomes from chemotherapy has been studied in many patient populations, including patients undergoing hematopoietic SCT (HSCT), 6, 8 which is frequently performed to improve the outcome of patients with hematologic malignancies and other hematologic or immunologic disorders. 6, 7 More than a dozen observational studies have suggested that overweight and obese recipients are at increased risk of adverse HSCT outcomes, including acute graft-versus-host disease (aGVHD), transplantation-related toxicity, infectious complications and overall survival (OS). 8, 9 To date, however, being overweight or obese has not been considered a proven risk factor in HSCT. 7 In this study, we conducted meta-analyses to evaluate the impact of obesity on aGVHD risk and OS in patients undergoing HSCT.
PATIENTS AND METHODS

Selection of studies
Meta-analyses were conducted in accordance with the PRISMA guidelines (Supplementary Table 1 , Supplementary Figure 1 ). Two authors (MN and DC) conducted a literature search for trials through computer-based searches of MEDLINE (PubMed), in addition to manual searches of references from relevant articles where necessary. The literature search used the following terms: (body mass index OR obesity OR overweight) AND (SCT OR BMT). Only papers written in English were included. The date of the last search was 30 September 2012. In cases of multiple publication of analyses using the same or overlapping data sets, only data from the largest or most recent study were included.
Procedures
Using the same data collection form, two investigators (MN and DC) independently abstracted the data to avoid bias, and subsequently compared the results. All data were checked for internal consistency, and disagreements were resolved by discussion. Studies that met the following criteria were analyzed: patients who underwent HSCT; being overweight or obese was evaluated as a risk factor for aGVHD or a prognostic factor; and relative risk (RR), odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) was obtained or calculable. The following information was then extracted: first author's name, year of publication, study location, year of transplantation, number of patients, underlying disease, median followup, median age (including age range), proportion of high-risk patients (patients with refractory or relapsed-phase malignant disease), type of HSCT (autologous or allogeneic), HLA matching status (identical or mismatch), conditioning regimen, methods of analysis (univariate or multivariate), methods of comparison (that is, definition of being overweight and reference group in individual studies), and RR, OR or HR with 95% CI for clinical outcomes (aGVHD and OS).
To estimate a summary RR for aGVHD and OS in patients who underwent HSCT, patients who were non-overweight versus overweight were compared. The definitions used to divide patients into the overweight or obese group versus the reference group differed among the studies. In the present study, we also categorized patients as overweight or non-overweight using the definitions in the individual studies. For aGVHD analysis also, the incidence of grade II-IV or grade III-IV aGVHD was used based on the definitions in the individual studies.
Statistical methods
Relative risks (RRs), including ORs and HRs, with 95% CI were used to assess the impact of being overweight on clinical outcomes after HSCT. If RRs according to both univariate and multivariate analyses were reported, we used the RR in the multivariate analysis. Study-specific RRs on the log scale comparing overweight or non-overweight patients were weighted by the inverse of their corresponding variances to obtain a pooled RR with 95% CI. If the overweight group was subdivided into two or more groups in individual studies, we combined the data of overweight and obese subgroups and presented the RRs of the combined overweight/obese group. All meta-analyses were conducted using a random-effects model. Heterogeneity among studies was examined by the Q-statistic. 10 Begg funnel plots 11 and Egger tests 12 were used to detect possible publication bias. To assess sources of heterogeneity, subgroup meta-analysis and meta-regression analysis 13 were performed. In meta-regression analysis we examined the following factors: transplant year (20th or 21st century), median follow-up (o36 months or X36 months), type of HSCT (allogeneic or autologous), HLA matching status (identical or mismatch), conditioning regimen (with or without TBI), patient age (pediatric or adult), proportion of high-risk patients (p50% or 450%), diagnosis (including or excluding acute leukemia), study location (Asia, Western or worldwide), type of control subjects (including or excluding underweight patients), definition of significant aGVHD (Xgrade III or Xgrade II) and analytical method (multivariate or univariate analysis). No adjustment of multiple comparisons was made because studies lacked sufficient statistical power and we had an a priori hypothesis. Statistical analyses were performed using STATA ver. 10 (StataCorp LP, College Station, TX, USA), with P-values of o0.05 considered statistically significant.
RESULTS
Selection of articles
A total of 261 potentially relevant articles were identified, of which 153 were excluded based on review of the title (Figure 1) . Abstracts of the remaining 108 articles were reviewed and 42 articles were retrieved for further consideration. Three additional articles were identified in the reference list of the candidate articles. After reviewing the 45 articles, 22 retrospective studies from 18 articles were identified for analysis. Table 1 summarizes the baseline characteristics of patients in each study. With regard to the risk of bias within studies, as all included studies were practical and observational and we did not have contact with the study authors, the risk of bias within individual studies was unclear.
Selection of studies for aGVHD analysis After reviewing the 18 articles, 8 studies from 7 articles were identified for aGVHD risk analysis, which included a total of 10 217 patients. 7, 9, [14] [15] [16] [17] [18] All articles were published in the 21st century and were limited to allogeneic HSCT. This meta-analysis included eight adult studies. With regard to baseline disease and disease stage, seven studies from six articles included acute leukemia and 48.96% of all patients were high-risk patients. Conditioning therapy without TBI was used in one article including one result. 16 Three studies from three articles used multivariate analysis, 9, 15, 18 whereas the remaining studies used univariate analysis alone. Two studies by Deeg et al. 19 presented the combined results of autologous and allogeneic HSCT, and were excluded from aGVHD analysis.
Selection of studies for OS analysis After reviewing the 18 articles, 21 studies from 17 articles were identified for OS analysis, of which six were also included in the aGVHD analysis. A total of 19 499 patients were included. 6,9,14-28 Table 1 summarizes the baseline characteristics of patients in each study. Four articles were published in the 20th century. 19, 23, 24, 26 Seven studies from six articles were limited to autologous HSCT, three studies from two articles were combined studies (including both autologous and allogeneic HSCT), 19, 28 and the remaining eleven studies from ten articles were limited to allogeneic HSCT. This meta-analysis included 3 pediatric studies, 19, 22, 28 12 adult studies and 6 combined (child and adult) or unknown studies. With regard to baseline disease and disease stage, 15 studies from 12 articles included acute leukemia and 54.1% of all patients were high-risk patients. Conditioning therapy with TBI was used in 14 studies from 11 articles. Twelve studies from nine articles used multivariate analysis, whereas the remaining nine studies used univariate analysis alone.
Definition of exposure variables
The definition of being overweight was a body mass index (BMI) greater than 25 kg/m 2 (refs 6,7,14-17,20,27) [22] [23] [24] 26 whereas the remaining 18 studies did not. 6, 7, 9, [14] [15] [16] [17] [18] [19] [20] [21] 25, 27, 28 The definition of significant aGVHD was as follows: grade III-IV in three studies, 7, 9, 18 and grade II-IV in the remaining studies.
Analyses of overweight and aGVHD risk
The results of the meta-analysis revealed a combined estimate RR of 1.186 (95% CI: 1.072-1.312). The forest plot of this analysis is shown in Figure 2 . When we added two studies by Deeg et al. 19 to this aGVHD analysis, we also observed a statistically significant risk elevation in the overweight population. The heterogeneity test in the aGVHD analysis showed no significant heterogeneity (P ¼ 0.446). Egger's test for publication bias was not statistically significant (P ¼ 0.055). We explored possible heterogeneity due to the following factors, none of which were significant: year of transplantation, area of transplantation, median follow-up time, Table 2 ).
Analysis of being overweight and survival
The results of the meta-analysis revealed a combined estimate RR of 1.122 (95% CI: 0.996-1.264). The heterogeneity test in the OS analysis showed significant heterogeneity (Po0.001). Egger's test for publication bias was significant (P ¼ 0.029) and a funnel plot showed asymmetry (Figure 3 ). When we divided the analysis into autologous and allogeneic HSCT studies, summary RRs for autologous and allogeneic HSCT were 0.95 (95% CI: 0.775-1.164) and 1.163 (1.009-1.340), respectively ( Figure 4) . In addition, when we excluded two studies that were published in the 20th century, summary RRs for allogeneic HSCT was 1.083 (95% CI: 0.948-1.238). In univariate meta-regression analysis, we explored sources of heterogeneity for OS by selected factors ( Table 2) . We observed significant heterogeneity in patient age (pediatric vs adult, P-heterogeneity ¼ 0.032; pediatric and adult vs adult, P-heterogeneity ¼ 0.028), proportion of high-risk patients (450% vs p50%, P-heterogeneity ¼ 0.054) and composition of control subjects (including vs excluding underweight patients, P-heterogeneity ¼ 0.003). Our meta-regression analysis for OS showed positive correlations with pediatric and combined (pediatric and adult) studies (coefficient, 0.519 and 0.473, respectively), but negative correlations with a higher proportion of high-risk subjects and inclusion of underweight subjects (coefficient, À 0.288 and À 0.542, respectively).
DISCUSSION
We conducted meta-analyses to determine whether patients who are overweight before HSCT experience inferior outcomes compared with patients who are non-overweight. We found a statistically significant impact of being overweight pre-transplant on outcome after allogeneic HSCT, but no significant impact on survival for autologous HSCT. Being overweight and obesity are known to increase the risk of numerous chronic diseases such as diabetes mellitus, cardiovascular diseases and hypertension. 1, 3, 20 These chronic diseases are thought to be associated with excess death among overweight subjects. 1 In addition, compared with non-obese patients, obese patients have altered pharmacokinetics for many medications. 25 These baseline diseases and pharmacokinetics in overweight patients may affect treatment outcomes, particularly for anticancer chemotherapy. Regarding high-dose chemotherapy accompanied by HSCT, no definite consensus has been established as to whether being overweight is associated with post-transplant outcomes. To our knowledge, this is the first metaanalysis regarding overweight patients and HSCT outcomes.
Our meta-analysis for aGVHD showed that risk is increased in the overweight population. Possible explanations are inappropriate doses of conditioning regimen, infused stem cells and GVHD prophylaxis in these patients. Particularly in the setting of stem cell doses, ideal body weight may be a better predictor of cell dose adequacy than actual body weight, and overdose of stem cells is suspected of being a risk factor for aGVHD. 29 Regarding GVHD prophylaxis, although the dose adjustment of calcineurin inhibitors is usually done through serum drug level monitoring, alteration of drug pharmacokinetics, such as drug distribution, in overweight patients might affect the outcome. 7, 8, 15 Other possible explanations involve cytokine-related mechanisms. Specifically, adipocytes secrete adipocytokines such as leptin, and leptin level is proportional to body weight and affects T-regulatory cell proliferation and function. 30, 31 In addition, obesity is likely associated with hyperglycemia, which might in turn result in an elevation of inflammatory cytokines. 15 These cytokine-induced Yes: all subjects were used TBI-based conditioning therapy, No: all subjects were used non-TBI-based conditioning therapy, Yes/no: both TBIbased and non-TBI-based subjects are included.
Overweight and SCT M Nakao et al changes in overweight patients may partially account for the findings of this meta-analysis. In our OS analysis, allogeneic HSCT analysis showed an increased risk in the overweight population. This increase might have been affected by the increased risk of aGVHD in this population. Further, several studies showed that obesity is associated with an increased risk of infection, and this is likely another possible explanation. 7, 15, 25 Compared with autologous HSCT recipients, allogeneic recipients are at an increased risk of serious infection, as they receive severe conditioning regimens and calcineurin inhibitors, which strongly suppress immune function. Being overweight before transplantation might therefore be associated with worse survival after allogeneic HSCT. When allogeneic OS analysis was limited to 20th century studies, in contrast, we detected no statistically significant impact of being overweight on survival. Progress in medical transplantation might have improved OS in overweight patients. Our meta-regression analysis for OS showed positive correlations with pediatric and combined (pediatric and adult) studies, but negative correlations with a higher proportion of high-risk subjects and inclusion of underweight subjects. Because chemotherapy dose adjustments based on weight to minimize toxicity are likely to differ between children and adults, the results of obesity studies in adult populations might not compare directly to studies in children. 9 In addition, these results of metaregression analysis might have also been affected by the heterogeneity of study settings and/or underlying disease characteristics.
In allogeneic HSCT, the effect of HLA locus mismatch on clinical outcome is a prime concern.
32 HLA mismatch is strongly associated with a higher risk of GVHD, and this is a very important drawback of this procedure. 32 In our analysis, however, we were unable to abstract details of HLA compatibility, and could only evaluate HLA matching status (identical or mismatch). In this regard, an individual data-based meta-analysis might have been beneficial, and a further study that can evaluate HLA compatibility in greater detail is warranted.
Our study has several methodological issues. First, although the sample size was considered to be sufficient, underlying diseases and HSCT procedure such as stem cell source, GVHD prophylaxis and conditioning regimen were variable, and it is therefore difficult to rule out potential heterogeneity across disease and HSCT settings. Second, we combined pediatric and adult studies. Outcomes between these studies are likely to differ, and our results should accordingly be interpreted with care. Third, the criterion of being overweight differed among studies. Given that the association between BMI and health outcomes differs not only between races 1 but also between age categories, 9 standardization of this definition might be difficult. In addition, obesity (BMI X30) in past studies was significantly associated with excess death, whereas being overweight (25pBMIo30) was not, 1, 33 indicating the need for additional evaluation focused on obesity. Fourth, the criteria for control patients differed among studies. Low BMI was Nikolousis et al. [7] Barker et al. [9] Unrelated Related Navarro et al. [17] Hadjibabaie et al. [16] Subtotal (I-squared = 0.0%, P = 0. Fuji et al. [15] Navarro et al. [17] Pine et al. [18] Subtotal (I-squared = 0.0%, P = 0.934) Subtotal (I-squared = 59.7%, P = 0.084) Year ES (95% CI) % Weight Figure 2 . Forest plots of relative risk in aGVHD analysis. The size of the squares corresponds to the weight of the study in the meta-analysis. Combined relative risk was calculated using a random-effects model. Overweight and SCT M Nakao et al reported to be associated with HSCT outcomes, 14, 16 and the inclusion of underweight subjects in the control group was statistically significant in our meta-regression analysis. This variation is therefore likely a source of heterogeneity in our study. Fifth, the variables used in multivariate analysis in individual studies may have been insufficient, and as variables considered in multivariate analyses differed among studies, this may also explain heterogeneity between studies. In addition, almost half of the RRs we abstracted from studies were univariate data. Regarding the statistical method of analysis (univariate or multivariate), we did not observe statistically significant heterogeneity in metaregression analysis.
Sixth, in each selected study, patients could not be randomized to the overweight group, and therefore the only practical method of evaluating impact was via an observational design. Our results should therefore be interpreted with care. Finally, our study had Study Autologous HSCT Tarella et al. [26] Meloni et al. [25] Navarro et al. [21] Navarro et al. [20] Navarro et al. [17] VogI et al. [6] VogI et al. [6] Subtotal (I-squared = 59.3%, P = 0.022) Allogeneic HSCT Fleming et al. [23] Hansen et al. [24] Le Blanc et al. [14] Bulley et al. [22] Fuji et al. [15] Navarro et al. [17] Auto/allo HSCT Deeg et al. [19] Deeg et al. [19] White et al [28] Subtotal (I-squared = 0.0%, P = 0.497) Overall (I-squared = 68.9%, P = 0.000) Figure 4 . Forest plots of relative risk in OS analysis. The size of the squares corresponds to the weight of the study in the meta-analysis. Combined relative risk was calculated using a random-effects model. Coefficient means how much the relative risk (RR) in the OS analysis is changed by the presence of a given factor or an increase of one degree.
Overweight and SCT M Nakao et al publication biases in both aGVHD and OS analysis. Although we performed a comprehensive literature search, small studies and studies that failed to show an association between being overweight and HSCT outcome are less likely to have been published. This might have led to an exaggeration of the results of our metaanalysis. Further, we abstracted data from English-language articles only and used PubMed search results only because of a lack of regular access to other databases. This might have introduced bias into our search strategy. Nevertheless, given the nature of the studies we sought, namely, clinical studies with adequate quality, our search within MEDLINE may have been sufficient.
In summary, our study indicated that being overweight before transplantation is associated with a higher aGVHD rate and worse survival after allogeneic HSCT. This finding might suggest that overweight or overweight-related diseases in patients have a significant impact on the outcome of HSCT with high-dose chemotherapy and GVHD prophylaxis. Given the heterogeneity such as adult/pediatric difference and publication bias identified among our source studies, a well-designed prospective study to evaluate the association between being overweight and HSCT outcome is warranted.
